Benzanthrone
Based on 1 Customer Validation
Benzanthrone is an immunotoxic, pro-inflammatory Photosensitizer. Benzanthrone upregulates iNOS, COX-2 and inflammatory cytokines; activates ERK1/2, p38, JNK, AP-1 and NF-κB; inhibits Nrf2; and induces oxidative stress and DNA damage. Upon radiation exposure, Benzanthrone generates singlet oxygen and superoxide anion radicals, induces photohemolysis and lipid peroxidation, and alters the levels of skin xenobiotic enzymes. Benzanthrone exhibits differential genotoxicity in different cell lines. Benzanthrone possesses skin tumor-initiating and promoting activities. Benzanthrone can be used in skin tumor-related studies.
For research use only. We do not sell to patients.
- Purity : 99.72%
- CAS No.: 82-05-3
- Formula: C17H10O
- Molecular Weight:230.26
-
Storage:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
Biological Activity
Description
IC50 & Target
[1]|
iNOS |
COX-2 |
ERK1 |
ERK2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | Inhibition |
127.309 %
Compound: BENZANTHRONE
|
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
[PMID: 23571415] |
| CHO | Inhibition |
69.7396 %
Compound: BENZANTHRONE
|
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
[PMID: 23571415] |
In Vitro
Benzanthrone (10 μM; 18 h) does not induce detectable DNA adduct formation in human A549 or HepG2 cells[2].
Benzanthrone (10 μM; 18 h) induces significant genotoxic lesions (DNA strand breaks/alkali-labile sites) in human A549 cells, but not in human HepG2 cells[2].
Benzanthrone (10 μM; 18 h) induces significant oxidative DNA damage in human A549 and HepG2 cells, with greater damage observed in A549 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Benzanthrone (0.3%; topical administration; once daily for 3 consecutive days, sensitization; 0.15%; topical administration; single dose, challenge) induces significant delayed-type hypersensitivity in female Balb/c mice, characterized by ear swelling, increased MPO activity, and inflammatory cell infiltration[1].
Benzanthrone (0.5-2.0 × 10-7 mol/cm2; percutaneous administration; single dose) acts as a potent skin photosensitizer in guinea pigs. After exposure to natural sunlight or simulated UVA radiation, the duration of its induced erythema, edema, pigmentation and skin toxicity increases in a dose-dependent manner[4].
Topical administration of commercial Benzanthrone (150 nmol; twice weekly for 30 weeks) induces abnormal changes in xenobiotic-metabolizing enzymes in mouse skin[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c (female, 6-8 weeks old, 18-20 g)[1]
-
Dosage:3.25 mg/kg; 7.5 mg/kg; 15 mg/kg
-
Administration:i.p.; daily; 1 week
-
Result:Caused dose-dependent inflammation at 7.5 mg/kg and 15 mg/kg.
Induced splenic hyperplasia with megakaryocyte infiltration, and lung alveolar septal thickening, edema, and focal hemorrhages at 15 mg/kg.
Showed no notable changes at 3.25 mg/kg.
Increased splenic MPO activity by 157% and lung MPO activity by 193% at 7.5 mg/kg.
Increased splenic MPO activity by 571% and lung MPO activity by 666% at 15 mg/kg.
Increased ROS generation (2-fold), lipid peroxidation (106%), and protein carbonyl content (25%); decreased GSH content (55%), SOD activity (24%), GST activity (37%), GR activity (34%), catalase activity (12%), and GPx activity (74%); reduced Nrf2 protein levels; and increased γ-H2AX protein levels (1.9-fold) in spleen at 7.5 mg/kg.
Increased ROS generation (2.9-fold), lipid peroxidation (450%), and protein carbonyl content (173%); decreased GSH content (73%), SOD activity (66%), GST activity (75%), GR activity (55%), catalase activity (29%), and GPx activity (85%); further reduced Nrf2 protein levels; and increased γ-H2AX protein levels (2.2-fold) in spleen at 15 mg/kg.
Increased TNF-α (1.2-fold), IL-4 (1.5-fold), and IL-1 (81-fold) in serum at 7.5 mg/kg.
Increased IL-17 (4.8-fold), TNF-α (1.52-fold), IFN-γ (4.2-fold), IL-4 (4.25-fold), IL-10 (12.3-fold), and IL-1 (427-fold) in serum at 15 mg/kg.
Dose-dependently increased mRNA levels of IL-4, IL-1, IL-10, IFN-γ, and TNF-α in splenic cytokine at 7.5 mg/kg and 15 mg/kg.
Increased p-JNK (2.5-fold), p-ERK (1.6-fold), and p-p38 (2-fold) at 7.5 mg/kg.
Increased p-JNK (2.9-fold), p-ERK (2.2-fold), and p-p38 (2.3-fold) at 15 mg/kg.
Increased p-NF-κB (1.8-fold), c-fos (1.9-fold), c-jun (2-fold), COX-2 (2.2-fold), and iNOS (2-fold) at 7.5 mg/kg.
Increased p-NF-κB (2.3-fold), c-fos (2.9-fold), c-jun (3-fold), COX-2 (2.9-fold), and iNOS (3-fold) at 15 mg/kg.
-
Animal Model:Balb/c (female)[1]
-
Dosage:0.3% (sensitization); 0.15% (challenge)
-
Administration:topical; once daily for 3 consecutive days (sensitization); single dose (challenge)
-
Result:Increased ear swelling by 69% compared to vehicle control.
Significantly elevated ear pinna MPO activity.
Induced epidermal hyperplasia protruding into the dermis and infiltration of mixed inflammatory cells.
Chemical Information
-
CAS No. 82-05-3
-
Appearance Solid
-
Molecular Weight 230.26
-
Formula C17H10O
-
Color Light yellow to yellow
-
SMILES
O=C1C2=C(C3=C4C1=CC=CC4=CC=C3)C=CC=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
In Vitro:
DMSO : 4 mg/mL (17.37 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tewari P, et al. Benzanthrone induced immunotoxicity via oxidative stress and inflammatory mediators in Balb/c mice. Immunobiology. 2015;220(3):369-381. [Content Brief]
[2]. Nagy E, et al. DNA adduct formation and oxidative stress from the carcinogenic urban air pollutant 3-nitrobenzanthrone and its isomer 2-nitrobenzanthrone, in vitro and in vivo. Mutagenesis. 2007;22(2):135-145. [Content Brief]
[3]. Ramdahl T. Polycyclic aromatic ketones in environmental samples. Environ Sci Technol. 1983 Nov 1;17(11):666-70. [Content Brief]
[4]. Srivastava LP, et al. Photosensitizing potential of benzanthrone. Food Chem Toxicol. 1990;28(9):653-658. [Content Brief]
[5]. Dwivedi N, et al. Skin tumorigenic potential of benzanthrone: prevention by ascorbic acid. Food Chem Toxicol. 2013;59:687-695. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.3429 mL | 21.7146 mL | 43.4292 mL | 108.5729 mL |
| 5 mM | 0.8686 mL | 4.3429 mL | 8.6858 mL | 21.7146 mL | |
| 10 mM | 0.4343 mL | 2.1715 mL | 4.3429 mL | 10.8573 mL | |
| 15 mM | 0.2895 mL | 1.4476 mL | 2.8953 mL | 7.2382 mL |